Physician profile
Amanda White
NPI 1013064203
$6,626.36
in general payments reported to CMS, 2019-2025
27 companies · $2,779 in 2025
The $2,779 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.46 · 2022: $218 · 2023: $1,277 · 2024: $2,334 · 2025: $2,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,141 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,141.23 |
| Education | $248.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,892.84 | 2022-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,082.45 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $677.26 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $487.85 | 2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $446.39 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $372.14 | 2022-2025 | Dupixent |
| Mylan Specialty L.P. | $229.06 | 2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $211.11 | 2024-2025 | Acthar |
| Verona Pharma, INC. | $169.72 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.60 | 2022-2025 | Spiriva Respimat, Stiolto Respimat, Jascayd |
| Amgen INC. | $143.01 | 2022-2024 | Tezspire |
| Optinose US, INC. | $119.76 | 2023-2025 | |
| Insmed, INC. | $119.05 | 2024-2025 | Arikayce, Brinsupri |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Electromed, INC. | $59.28 | 2025 | Smartvest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $53.12 | 2025 | |
| Lilly USA, LLC | $49.78 | 2025 | Zepbound |
| Harmony Biosciences LLC | $36.23 | 2022-2025 | |
| Vifor Pharma, INC. | $36.14 | 2025 | Zemaira |
| Inspire Medical Systems, INC. | $35.64 | 2024 | Inspire |
| Genentech USA, INC. | $32.07 | 2023 | Xolair |
| Philips North America LLC | $31.85 | 2025 | Vest Therapy Und |
| Angiodynamics, INC. | $23.24 | 2025 | Bioflo |
| E.R. Squibb & Sons, L.L.C. | $21.22 | 2023 | Eliquis |
| Emd Serono, INC. | $18.46 | 2021 | |
| Covis Pharma Gmbh | $18.17 | 2023 | |
| Novo Nordisk INC | $16.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.